The Effectiveness of Face-To-Face Counseling and Telenursing on the Drug Adherence for Individuals Suffering From HIV/AIDS

Muhammad Haris Faisal¹, Sri Yona²

¹Magister Program of Nursing, Nursing Science Faculty, Universitas Indonesia, Depok, Indonesia ²Nursing Science Faculty, Universitas Indonesia, Depok, Indonesia

Corresponding Author: Muhammad Haris Faisal

DOI: https://doi.org/10.52403/ijshr.20230223

ABSTRACT

This research compares the intervention effectiveness of face-to-face counseling and telenursing method on the Anti-Retroviral medicine consumption adherence for individuals suffering from HIV/AIDS.

The method: researchers explored the data from EBSCOHost, science direct, ProQuest, springer nature, and PubMed within the period of 2018 and 2022. The exploration found 1.521 journal articles plus their abstracts. Out of 1.521 journal articles, the researchers found 10 articles examining the effectiveness of counseling-based digital media for both computers and applications on mobile.

Results: 10 studies used the mHealth platform, virtual counseling, digital media, computerbased technology, and mobile. The assessments on the ARV medicine consumption adherence applied CD₄ and viral load checkup. On the other hand, the researchers found the assessment of the ARV medicine consumption adherence applied Electronic Dose Monitoring, EDM, to examine the missing doses. The researchers found electronic pill monitoring or eCAP to ARV medicine examine consumption adherence. The other assessment was the Visual Analog Scale, VAS, to report the side effects. Then, the last assessment was an autonomous self-report to remind the medical visits via phone calls.

Conclusion: face-to-face counseling allows counselors to examine the clients' responses, transmission risk, and ARV medication hindrances directly. The counselors could also find the solution to deal with the problems and

observe the allergic reactions to the medication or other complaints due to immunosuppressive. The researchers also concluded that technology could facilitate the service distance, save time and cost, provide accessible health, provide nursing health care, provide immediate responses, and become the support system for the clients to consume the medicines. However, the roles of face-to-face counseling are irreplaceable.

Keywords: [Counseling, telenursing, drug adherence, HIV/AIDS]

INTRODUCTION

Human Immunodeficiency Virus, HIV, destructive refers to aggressive and infections against human immunity. specifically the white blood cell or CD4 cell (T-cell). Along with the disease development, opportunistic infections may occur, such as losing weight drastically, chronic diarrhea with unclear causes repeated oral candidiasis, and cancers, as observed in the phase of AIDS, Acquired Immune Deficiency Syndrome. (1)

Anti Retroviral (ARV) is an effective clinical intervention to control HIV replications. (2),(3) Therefore, the patient's adherence to treatment is important to suppress HIV. Viral suppression prevents medicine resistance and pain. Therefore, individuals can improve their life quality, prevent HIV transmission to other individuals, and lower the mortality rate. (4)

The importance of sustainable and consistent medicine consumption adherence to suppress the virus and HIV transmission requires high adherence, more than 95%. Thus, ARV medicine must be consumed punctually without any missing for the rest of the individual's life. Unfortunately, many patients did not commit to consuming the medicine regularly, and this influenced their resistance (3)

Medicine consumption adherence refers to the capability of individuals to obey and implement the therapeutic recommendation by medicine providers, starting from the drinking method, consumption time, consumption frequency, and dose. (5)

Low ARV medicine consumption occurs due to the fear of being isolated and neglected. This problem occurs due to community stigma, discrimination, depression, lack of HIV awareness, and lack of social support. (6) The adherence to consuming ARV medicine maximizes the viral load suppression in the body, prevents damage to CD4, and hinders the AIDS stages. (7)

The initial care and treatment after HIV diagnosis are important to control the disease and decrease HIV transmission. The care and the treatment are also useful to improve the life quality of individuals suffering from HIV. The WHO recommends these individuals get counseling to manage their anxiety. (8)(9)

Based on Indonesia's Dictionary, counseling refers to guiding experts for individuals. The guidance applies the psychological method to direct and assist the clients. Thus, the clients can understand their skills, improve themselves, and solve problems. The counselor provides ART counseling to improve the patient's awareness of HIV, prepare the patients, and provide the principles of long-life medicine adherence. The principles of ART counseling are: focused on the client's needs accurately and adequately, provide information about HIV, provide information about medicine consumption adherence and resistance, support the emotional aspect of HIV clients to live and encourage the supportive medication for seeking emotional support from the spouses(10).

The implementation of recent technology has fast development in telehealth. The supportive health technology for patients' medication management can be integrated with various media, such as mobile health(mHealth)(11) and telenursing(12). Telenursing refers to the implementation of technology to provide telecare and actions for patients based on their needs. (12).

HIV/AIDS problems also encounter problems to prevent, medicate, and provide health care. One of the crucial problems is consuming ARV medicine. ARV therapy program, in the long-term, requires the patients' commitment to consume the medicine punctually and discipline with a consumption schedule. stitch The consumption cannot be missed because the medicine is useful to suppress the virus development. Therefore, further innovations from various disciplines are important to medicate and prevent HIV transmission. The other method to ensure medicine consumption medication and promotes the efforts of preventing secondary HIV risks involves preventive HIV behavior and behavioral changes by using technology. In this research, the researchers focused on the effectiveness differences of face-to-face counseling and telenursing on the ARV medicine consumption adherence of individuals suffering from HIV/AIDS.

MATERIALS & METHODS

From the background, the researchers analyzed the effectiveness of intervention between face-to-face counseling and telenursing on ARV medicine consumption adherence for individuals suffering from HIV with a literature review approach. This literature review used some databases, such as EBSCOHost, science direct, ProQuest, springer nature, and Pubmed, to find international journal articles and national journal articles. The databases were also useful to find other sources, such as news directories support to the research

comprehensiveness. In this case, the applied keywords were "Telehealth," or "telenursing," and "HIV/AIDS," and "faceto-face," or counseling," and "adherence." The articles should be published between 2018 and 2022 and written in Indonesian language and English.

The researchers explored the literature with a randomized controlled trial. The results were articles based on the criteria in the journal article database. In this process, the researchers found 10 relevant articles.

RESULT

This literature review summarized 10 relevant articles about the effectiveness of standard counseling as the reference of mHealth or mobile health-based technology application. Then, the researchers compared the effectiveness of the application with the standard counseling attempt to improve ART adherence. In this research, the researchers also investigated the combination of mHealth with medicine reminders, electronic signaling to remind medicine consumption, and identification of ART adherence against the challenges. From the research articles, the researchers found research that applied intervention and control group with the implementation of digital-based Internet. This researcher differentiated the intervention group with virtual group counseling via the Telegram application. (13) The other nine studies provided intervention with some media, such as the mHealth platform (10,15–17), virtual counseling (18), digital media application (19, 20),computer-based implementation (21), and cellular phones. (19) The researchers summarized the medicine consumption adherence with CD4 and virtual load checkup (10,15–17,19–21). The researchers also found a technique to measure the patients' adherence. (13) The other measurements were the implementation of Electronic Dose Monitoring (EDM) to remind the missing

doses. (14) Electronic Pill Monitoring was check ARV consumption useful to adherence via Electronic Monitoring called eCAP.(21,22) Then, the researchers also found the implementation of the Visual Analog Scale, VAS, to check the side report the medicine effects or to (21) consumption independently. The reminded utilized phone calls. (20) On the other hand, the measurement of adherence levels to check the patients' pre-exposure prophylaxis on YMSM and YTGW PrEP with TEVDP measurement in the third and sixth months.

The PrEP adherence was correlated with the TFV-DP level for more than 700 fmol/punch (14), the checkup of CD4 cellular amount and viral suppression (19), the ART adherence for chronic medication with the questionnaire of AIDS Clinical Trial Group adherence or ACTG.(23)

Many inpatient patients have limited experience and are unreadiness to have long-term medicine consumption commitments (51, 52, 53). The first years for newly cared individuals are the vulnerable and critical moment for the individuals to adapt (54). Specifically, individuals suffering from HIV began their ART to suppress the viral load (VI) and optimize their health (51,54-44).

The appearing stigma related to HIV becomes the hindering factor for individuals to keep their HIV medication adherence. This stigma is a complex social process in which individuals suffering from HIV received negative prejudice, de-evaluation, discrimination, denial, and other negative attitudes because of their life suffering from HIV. This matter makes the individuals suffering from HIV delay their efforts of seeking HIV health care services and ART. Thus, they miss the clinical visit which leads to delayed VL suppression, viral load, cumulative rate, and increased mortality and morbidity.

| | | Table 1 study | population, design, | interventions, | outcomes, and results | 6 | |
|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Author, year, study location | Study population, sample size (screened, enrolled, completed, followed) | Study design | Main intervention and comparison/cont rol | Outcome measures: Viral Load | Outcome measures: other symptoms | Results: Viral Load | Results: other symptoms |
| H. Gouse, 2018, primary health care clinic in Cape Town South Africa's. | Intervention N= 250 patients with HIV diagnosis. Control: N=337 patients | The research applied randomized controlled trials; September 2012 until May 2017; pre-post- intervention study design. The researchers trained the counselors to use <i>masivukeni</i> (a based on the local culture and language). The average duration for each minute per counseling session was 42 with an SD of 20.04 for the first session, 39 minutes with an SD of 21.08 for the second session, and 49 minutes with an SD of 27.15 for the third | Intervention: The primary intervention was the application of <i>masivukeni</i> , a multimedia counseling application Control: a study on a standard of care (SOC) | The viral load measureme nt becomes the viral suppression results. | the patients' awareness about HIV and ART The patients' attitudes toward the ART The anxiety and depression levels calculated | After 12 months, 90% of the patients, 337 out of 456 women (73%), with an average age of 33 years old, within the group of astandard of care (SOC), could reach the viral load suppression lower than 400 copies/mL. The patients received the <i>masivukeni</i> more than 12 times. The patients might suffer from high VL suppression than those with the standard of care. | AFTER the intervention, patients suffering from HIV/AIDS had significant awarness, attidudes and anxiety depresion cognitive p- value 0.001. the counselors also reported that they were more confident and could provide better counseling after applying <i>masivukeni</i> application. The research showed more patients with <i>masivukeni</i> began their ART medication than the control group. |
| Amico et al, 2022 United States (US) | Screened (n=108): The unlisted (n=19), HIV- 1 RNA lower than 200 cp/ml (n=15), patients without consuming pill/day (n=1), tarv for more than 24 weeks before HIV-1, RNA higher than 200 cp/ml (n=2), having no clinical visit (n=3) Randomizati on (n=89) The | The researcher used a randomized controlled trial, RCT; distant- medication reminder intervention for the intervention group or standard care for the control group. The research target consisted of 120 youngsters taken randomly with equal | Intervention: The intervention group received distant medication reminders from the cellular application, mHealth, and the distant counseling training to improve Anti Retroviral therapy adherence; 12 weeks by a trainer based on the applied schedule as shown in Vsee, a video conference platform, at the beginning of the clinical visit. Control: | The virology suppression is defined as the HIV- 1 plasma, RNA lower than 200 copies/ml in the twelfth week (± 2 weeks). The failure is defined as the HIV- 1 in the twelfth week, RNA lower than 200 copies/ml without viral load test. | The adherence level on the medicine (self- reported) The life quality related to health (counted with a questionnaire) The correlation with the care (counted with a questionnaire) | The intervention group showed a significant decrease in viral load than the control group in the twenty-fourth week with the baseline (average mean of -0,56 log10 copies/ mL, vs0,06 log10 copies/ mL, $p = 0,01$). The intervention effect of weekly | The intervention group had a significant improvement in terms of medication adherence, p- value lower than 0.0001. The related- health quality life obtained a p-value of 0.005 with a correlation toward care (p- value = 0.004) than the control group. |

Table 1 study population, design, interventions, outcomes, and results

| | intervention: | probability. | Standard of Care | | | viral | |
|---------------|-----------------------|--------------|-----------------------------------|--------------|-------------------|-------------------------|------------------|
| | (n=43), the | Thus, the | | | | suppression | |
| | control | probability | | | | in the | |
| | group: (n-46) | was the same | | | | twenty- | |
| | (II=40), expelled | group and | | | | showed 36 | |
| | from the | SOC group. | | | | and 48 | |
| | system 1. | ~~~ 8F | | | | women had | |
| | Intervention | | | | | lower viral | |
| | n=43 | | | | | suppression | |
| | Complete | | | | | than males | |
| | n=38 Incomplete | | | | | with PNA | |
| | n=5 | | | | | lower than | |
| | Control n=43 | | | | | 200 | |
| | Complete | | | | | copies/mL. | |
| | n=43 | | | | | The women | |
| | Incomplete | | | | | and the | |
| | n=2 Pro covid | | | | | male had $PR of 0.60$ | |
| | Intervention | | | | | 95% and | |
| | n=38 | | | | | Cl of 0.45. | |
| | Complete n | | | | | (1,05 CI | |
| | = 22, Incomplete | | | | | 0,45, 1,05; p = 0,09 | |
| | n=3 | | | | | and HIV-1 | |
| | Control n=43 | | | | | RNA < 50 | |
| | Complete n -17 | | | | | copies/mL | |
| | = 17, Incomplete | | | | | = 0.05, 93% | |
| | n=10 | | | | | 1.03. p = | |
| | - | | | | | 0,07). | |
| | Stopped | | | | | | |
| | post-covid | | | | | | |
| | 19 studies, | | | | | | |
| | Intervention $n-32$ | | | | | | |
| | complete $n =$ | | | | | | |
| | 10, loss | | | | | | |
| | follow up = | | | | | | |
| | 3, Control | | | | | | |
| | n=31 | | | | | | |
| | complete $n =$ | | | | | | |
| | 14, loss | | | | | | |
| | follow $up = 2$ | | | | | | |
| | Total sampel | | | | | | |
| | N=63 | | | | | | |
| | Intervention $(n-32)$ | | | | | | |
| | The control | | | | | | |
| | group: | | | | | | |
| | (n=31) | | | | | | |
| Kurth et al., | 586 people | The | The intervention: | Viral Load | Self reporting | The control | The report |
| 2019 Kar | from two | researcher | CARE+ | HIV-1; | sexual activity | group had a | showed the |
| Kenya. | research | used a | counseling in Keya was tablet: | Electronic | Without condoms | decreased | intervention |
| | people | controlled | guided by the | The log-10 | orme rab. checked | more than | behavior. |
| | agreed (40% | trial, RCT; | counseling; 30 | evaluation | | $0.5 \log 10$ | control |
| | accepting); | From | until 60 minutes | found | | and was | Sexual |
| | 236 were | September 1, | intervention | different | | clinically | intercourse of |
| | randomized | 2011, until | Control: | viral loads | | and | 56% for each |
| | and finished | July 12, | The consultation | between the | | statistically | group |
| | ine initial | follow-up | direct assessment | interventio | | significant | for 34% · 35% |
| | and a | continued | of behaviors: 15 | n groups | | The viral | Using broken |
| | percentage of | until April | minutes. | with | | load in the | condoms of |
| | 95% or 225 | 2013 while | Each group had a | samples | | intervention | 97%:96% |
| | people | the | total of four | from both | | phase was | Violent |
| | maintained | implementati | sessions for 3 | groups to | | 0.96 VS | intercourse with |
| | for 9 months | in 2014 | monuis. | HIV-1 viral | | control | 9%: 12% |
| | ior > monuis. | | | loads in the | | group (0.80 | Violent |
| | | Intervention | | first and | | vs 1.34). | intercourse with |
| | | (n=118) | | ninth | | The viral | other spouses: |

| | | control | | months. | | load was | 0%1% |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | (n=118) | | | | significantl | The urine check |
| | | The risk | | | | y lower | was useful to |
| | | assessment | | | | after nine | measure the |
| | | and were | | | | months than | communicable |
| | | for 0 months | | | | the viral | sexual infection |
| | | with | | | | ioau at | intervention |
| | | retention of | | | | intervention | group: the |
| | | 95.3%. | | | | | control group |
| | | 2010/01 | | | | The | Chlamydia. |
| | | | | | | autonomous | each with 2% |
| | | | | | | reported | Gonorrhea, |
| | | | | | | VAS by the | each with 3% |
| | | | | | | intervention | T. vaginalis, |
| | | | | | | group; the | each with 4%: |
| | | | | | | VAS | 9% |
| | | | | | | adherence | On the other |
| | | | | | | the control | hand the |
| | | | | | | group was | missing clinical |
| | | | | | | between 77 | visits of both |
| | | | | | | and 99: 88- | groups were |
| | | | | | | 99 (90:95) | 83%: 76 % |
| | | | | | | VAS scale | |
| | | | | | | higher than | |
| | | | | | | 95% was | |
| | | | | | | 44%: 55% | |
| | | | | | | Log 10 | |
| | | | | | | load mean | |
| | | | | | | (1.56; 1.36) | |
| | | | | | | Undetected | |
| | | | | | | viral load, | |
| | | | | | | 6%: 67% | |
| YIGIT et al, | 941 | The | The intervention | Viral | The followed up | The viral | The |
| 2022, USA | participants | researcher | group: The | suppression | assessment in the | load in the | measurement of |
| | were enlisted | used a | patients received | tor 48 | 48 th week found | 48 th week of | RM ANOVA: |
| | 1 | 1 1 1 | | 1 | 10 Week Iound | 214 | |
| | and | randomized | four sessions of | weeks | the connection | 314 | The significant |
| | and screened. | randomized controlled trial RCT: | four sessions of face-to-face | weeks | the connection with internalized | 314 participants | The significant primary time effect $F(1,298)$ |
| | and screened. 573 participants | randomized controlled trial, RCT; The | four sessions of face-to-face meetings (0-2, 2- 12 12-24 and | weeks | the connection with internalized HIV stigma, depression | 314 participants was 85% of the | The significant primary time effect, F (1.298) = $n = 0.002$ n 2 |
| | and screened. 573 participants were not | randomized controlled trial, RCT; The intervention | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks | weeks | the connection with internalized HIV stigma, depression symptoms. | 314 participants was 85% of the iENGAGE | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03. |
| | and screened. 573 participants were not active. 183 | randomized controlled trial, RCT; The intervention group | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and | 314 participants was 85% of the iENGAGE sample, | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV |
| | and screened. 573 participants were not active. 183 participants | randomized controlled trial, RCT; The intervention group (N=185); the | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the | 314 participants was 85% of the iENGAGE sample, including | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during |
| | and screened. 573 participants were not active. 183 participants did not | randomized controlled trial, RCT; The intervention group (N=185); the control group | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. | 314 participants was 85% of the iENGAGE sample, including 155 | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention | 314 participants was 85% of the iENGAGE sample, including 155 participants | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the | 314 participants was 85% of the iENGAGE sample, including 155 participants from the | The significant primary time effect, F (1.298) = $p = 0.002$, $q 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention | The significant primary time effect, F (1.298) = $p = 0.002$, $q 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) | The significant primary time effect, F (1.298) = $p = 0.002$, $q 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the proceed. | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 | The significant primary time effect, F (1.298) = $p = 0.002$, $q 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the interpretion |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the | The significant primary time effect, F (1.298) = $p = 0.002$, $q 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustration | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial cond th |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative mattere to | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.003, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve doses in certain | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of depression |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve doses in certain places | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of depression against the |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve doses in certain places | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of depression against the decreased HIV |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve doses in certain places | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of depression against the decreased HIV stigma was intervention |
| | and screened. 573 participants were not active. 183 participants did not agree. 14 participants agreed but they did not enlist:4 | randomized controlled trial, RCT; The intervention group (N=185); the control group (N=186) | four sessions of face-to-face meetings (0-2, 2- 12, 12-24, and 24-48 weeks after the randomization); The participants received personal contact calls, visit reminder call, and missing visit call during the research. The control group: the standard care including strategies to support adherence and ART retention during the care, such as illustrative matters to provide information and encourage the participants to store the reserve doses in certain places | weeks | the connection with internalized HIV stigma, depression symptoms, coping, and mechanism as the secondary results. The intervention influenced the internalized HIV stigma change. | 314 participants was 85% of the iENGAGE sample, including 155 participants from the intervention group (84\$) and 159 participants from the control group (85%). The results showed strong retention. | The significant primary time effect, F (1.298) = $p = 0.002$, $\eta 2$ p = 0.03, indicated HIV stigma during the follow-up period (M = 2.17, SD = 0.73). The follow-up on the intervention group found a decrease in HIV stigma from the initial condition. The control group had no significant differences between the initial and the follow-up conditions in terms of HIV stigma. The primary effect of depression against the decreased HIV stigma was internalized incimifecently |

| Songtawees in et al. 2020, Thailand | Research time March 2018 to June 2019 489 listed adolescents, 147 YMSM participants, 74%; 53 YTGW (26%); 27 positive HIV patients (6%) Sample 200 (41%) intervention =100 control= 100 | The study design: The randomized control test pre-exposure prophylaxis, PrEP; and a specific cellular- designed application to improve PrEP adherence. mobile phone app, YFS + APP on the clinical months of 0, 1, 3, and 6. The researchers also called the participants in the second, fourth, and fifth months. | The intervention: Receiving Youth- Friendly Services Plus App The control group: The control group received YFS with the adjusted topic based on the individuals' needs, starting from education, sex orientation (lesbian, gay, bisexual, and transgender), stigma, discrimination, mental health problem, compound abuse, and specialist reference. All clients had access to trans-gender counseling and related blood test to confirm the gender and hormonal therapy | PrEP adherence was measured by TFVDP in the third and sixth months. The determined PrEP adherences were about the participants ' TF-DP level, higher than 2700 fmol/punch | Measured by: HIV infection level, Retention level study on the sixth month, and the related PrEP adherence factor The risk protection of HIV transmission was consistent (100% condom consistency) | The PrEP adherence in the third month was: 51% on YFS and 54% on YFS + APP (p-value of 0,64) The PrEP adherence in the sixth month was: 44% on YFS and 49% on YFS + APP (p-value of 0,54) The PrEP adherence levels by TFDVP were on the third month = (95% CI 45 -60) and On the sixth month with 51%, receiving YFS and 54% for YFS + APP (p = 0.65); then on the sixth month with 44%, receiving YFS and 54% for YFS + APP (p = 0.65); then on the sixth month with 44%, receiving YFS and 49% for YFS and 54% for YFS + APP (p = 0.65); then on the sixth month with 44%, receiving YFS and 49% for YFS and 54% for YFS and YFS and YFS and YFS and YFS and YFS and | The HIV infection level; is 27 with positive HIV (6%) 13% of participants reported the recent 3 months of consuming drugs The respondents also reported their habits of drinking alcohol (6%), amphetamine or methamphetamin ne (4%), ketamine (0.5%), popper (the evaporated alkyl nitrite 5%), cannabis (2%), and sildenafil citrate (4%). The retention level on the sixth month was 73%, observed on the sixth- month follow- up, 72% on YFS, and 73% on YFS + APP (p=0.87). The condom application was consistent, for 34% (95% CL 25 until 43) in the beginning into 58% (85% CL 49 until 68) in the third month with a p- value lower than 0.0001. In the sixth month, the value |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jiao et al. | The | The study | The intervention: | The Viral | of life quality | $\frac{\text{YFS} + \text{APP}}{(p = 0.54)}$ The intervention | until 62. The self- |
| China. | were males having sexual intercourse with males suffering from HIV. from October 19, 2020, to June 31, 2021. n=576 Intervention: n = 288; Control n = 288 Three | randomized- controlled intervention test: The participants could choose one of three digital strategies, starting from the textual message, instant message, or instant and social media | cerved uniferent care with the assistance of information and communication technology, including the SMS-based reminder and ICT counseling service support to improve ART therapy adherence. <u>Control:</u> received standard care with direct reminders and | Measureme nt The ART adherence level The T-cell or CD ₄ cell amount checkup, viral suppression , and | WHOQOL-BREF questionnaire. self-efficacy, | reported highly improved adherence toward ART than the control group's adherence in the third month (99,3% vs 94,2%, p=0.047) and sixth month | ARV medication adherence for each textual- based intervention was 1.24 (-1.55, 4.02), the instant-based message intervention with 1.67 (- 0.26, 3.61), and the combined intervention of instant and social media |

| | month- follow up, n = 241 Intervention: n = 288; Control, n = 259, Six months follow-up, n = 245 Intervention: n = 245; Control n = 256 | message. WeChat was for instant messages and QQ was for social media message | face-to-face counseling. The participants also received additional messages, such as behavioral health and nutritional health, based on routine care. | | | (97,1% vs 83,0%, p<0,001). After the intervention , the participant proportion reaching the optimum ART adherence was high for the intervention group (82.9% vs 71.1%). The different digital intervention s had significant improveme nt in ART adherence (RR = 1,74, 95%CI 1,21–2,50). Viral Load: the intervention group members had a higher decreased the control group's viral load median (-2,06 vs - 1,59 log10 | with 0.27 (- 3.45, 3.99). The life quality scores: text- based intervention - 1.50 (-3.24, 0.25), instant message-based intervention with 0.85 (- 0.43, 2.13), and the combined intervention between instant and social media group with 1.66 (- 0.16, 3.47). The result showed no significant difference between the intervention and control groups in terms of life quality score. |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Schnall et al. 2018 New York USA | $\begin{array}{l} N=80,\\ Control n=40\\ lost to\\ follow-up\\ n=1\\ Having no\\ follow-up\\ schedule,\\ n=1\\ Intervensi\\ n=40\\ lost to follow\\ up n=3\\ Having no\\ follow-up\\ schedule,\\ n=2\\ Obstructed\\ intervention,\\ n=1 \end{array}$ | A randomized clinical; recruited the respondents via local brochures, HIV clinics, community- based organizations , and invitation emails; the research assistant assessed the respondents in terms of reliability based on the inclusion criteria. | The intervention group: mVIP with self-care strategy The control group: mVIP without self-care strategy Both groups received access to the mVIP application on their smartphones | The CD4 amount Viral Load | The reported frequency of the participants Indicating symptoms on life quality | $\begin{array}{rrr} p<0.001).\\ \hline The CD_4\\ amount > \\ 500\\ \hline The total\\ amount:\\ (n=42)\\ (53,2\%)\\ \hline The\\ intervention\\ group\\ (n=40) was\\ 22, 55.0\%\\ \hline The control\\ group (n = \\ 40) was 20, \\ 51.3\%\\ \hline Virologicall\\ y\\ Desuppress\\ ed\\ \hline The total\\ amount:\\ (n=68)\\ (85,0\%)\\ \hline The\\ intervention\\ group\\ (n=40) was \end{array}$ | intervention: Fatigue (n = 61, 76,3%), Having insomnia (n = 59,74,7%), Neuropathy (n = 45,57,0%), Depression (n = 43,53,8%). cotnrol: Anxiety (p = 0,001). Depression (p = 0,001), Neuropathy (p = 0,002), Fever, chilling, and sweating (p = 0.037), and Losing weight (p = 0.020) The control group indicated higher nausea and vomiting than the |

| | | | | | | 34, 85.0% The control group (n = 40) was 34, 81.0% | intervention group insignificantly. |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Magidson et al., 2022 Northeast Washington DC, USA | Client interviewed and screened for study participation N=878 Completed baseline assessment and randomized N=61 Intervention N= 32 participants Control: N=29 participants | controlled- random clinical test; participants randomly and in parallel (1:1) to receive one of Act Healthy (AH; BA+life Steps or (2) Supportive Counseling, SC+Life Steps). | Intervention: Healthy (BA + Life-Steps)—Act Healthy Combined BA to use compound, LETS ACT, with the immediate problem-solving intervention for HIV-related self- care, including the initiation of ART, adherence, and sustainable involvement in the care (Life- steps). Control: Supportive Counseling (SC) + Life-Steps SC | The results of the ART adherence in terms of chronic medication required the adherence questionnai re of AIDS Clinical Trial Group, ACTG. | These compound administrations were assessed by two measurements: The urine screening was done with 5-panel parallel cups of E- Z split to examine the cocaine, amphetamines, phencyclidine (PCP), tetrahydrocannabi nol (THC), and opiates. The participants reported depression symptoms with 21 Back Depression inventory items. The motivation for using compound administration applied compound administration measurement with a Conditional Scale. | The results showed a significant difference between the groups' intercepts (SC=13.05, AH = 6.86, p = 0.009). The mean of the follow-up action was 67%, n = 41. The assessment for six months was 61%, n = 37. Both groups had a significant increase from 57% to 86%. | The problems of administrating cocaine (56.7%), alcohol (31.7%), and opioids (25%) . Here are the visits of the last follow-up assessment: 67% (n = 41) for the six- month follow- up and 61% (n = 37) for the twelve-month follow-up. The compound administration; the OR compared the importance level of each primary point of time between AH and SC, ranging between 0.42 (0.10, 1.68) - 2.52 $(0.56, 9.83)$. |
| Gross et al., 2022 Afrika, Asia, dan Amerika | 1091 participants were reliable. 546 participants were excluded because 351 participants did not meet the inclusion criteria RNA, HIV- 1; 45 participants had closed screening, and 150 participants had different reasons. 545 primary study, 24 participants were excluded; n=257 MPI group n=264 SOS group | controlled- randomized design to compare the intervention effect of the active behavior group and the control group (1:1). The Internet web-based computer in the central computer, the researchers took a participant randomly from the group receiving phone calls plus standard of care, SOC. | The intervention: the intervention of phone call plus local standard of care adherence support (MPI + SOC) The control group: participants receiving only standard of care, SOC. | Viral Load (log10/) The measureme nt of RNA HIV-1 = 200 exemplars per mL or less than the forty- eighth week in both groups. Continuing the second- phase ART | The virological failure time, other symptoms (scales between 0 - 10) The CD₄ changes The ART adherence and the reported side- effects | After 48 weeks, the researchers found no significant differences in terms of viral load between the intervention and control groups (the mean difference: 0,01; 95% CI, -0,09 until 0,10; P = 0,85) Patients with ≤ 200 exemplars per mL on the forty-eighth week The group of MPI + SOC = 169/257 (66%) The SOC group = 164/264 (62%) | The scores of other significantly decreased symptoms in both groups (the intervention group: average decrease of 1.42; the control group: average decrease of 1.47), the mean differences: 0,05; 95% CI, - 0,19 until $0,29;P = 0,67The virologicalfailure timeThe group ofMPI + SOC =66/257 (26%)The SOC group= 89/264 (34\%)Continuing thesecond phaseARTMPI + SOC=60/133 (45%)The SOC group= 75/136 (55\%)The CD4AmountChangeThe personalcounseling$ |

| | | | | | | Continuing the second phase ART The group of MPI + SOC = 60/133 (45%) The SOC group = 55/136 (40%) | after the ART changes (94%- 100%) personal counseling before or during the ART changes (94%) The immediate services at clinics (7-82%) The pill calculation; 71%-82% The transport change (58%- 71%) The phone call follow-up (47%-59%), and HIV education for families/friends |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mogart et al., 2022. Atlanta, USA | The population consisted of black African adults living with HIV and receiving ARV. The research lasted from January 2018 to December 2021 The recruitment: January 2018 to July 2020 Intervention group: n = 85 Control group: n = 81 | randomized controlled trial, RCT; two group, intervention and control The assessment of adherence ended in June 2021; the viral load assessment Ended by the medical record on December 2021 | Intervention: The intervention session was led by a peer counselor from black people; two-day training with basic MI patterns (reflective and educative) for 6 months in 5 sessions. Intervention group received routine and sustainable care from the health care provider and received an ART prescription. | The researchers took the blood with a venipunctur e technique to determine the HIV viral load in FQHC, an HIV service organizatio n, before the pandemic. During the pandemic, the services were absent so the participants were accompanie d by transport service to the local laboratory. Besides that, the participants reported the dates and the HIV viral load test results at the beginning of the research and the follow-up. | The adherence assessment of consuming the medicine with MEMs lasted daily and electronically for 1 until 3 months. The researchers used the MEMs cap to record the dates and the times of unsealing the bottles. The researchers also analyzed the other HIV symptoms as secondary results. | More than 80% of participants had viral suppression and a percentage of 61% had used 75% of the prescribed dose. The autonomous report of viral suppression obtained a percentage of 71.7% found in the control group and the intervention group a percentage of 73.9%. The rising effect of adherence was stronger for younger patients with log- odds (se) = y 0.06 (0.03), p = 0.03. For participants aged 1- year-old, the SD was below the average. The intervention effect was stronger for | (41%-47%) The results showed 75% adherence was highly found in the intervention group than the control group OR (95% CI)=2.0 (1.1– 3.6), p=0.03, Cohen's d=0.4; 29% of respondents were positive to suffer from depression; stigma ; and The serostatus of HIV baseline: the follow-up lasted 13 months for the intervention group with a percentage of 96.0%: 96.6% while the control group had percentages: of 96.7%: and 98.9% |

| | [OR (95% |
|--|--------------|
| | CI)=5.4 |
| | (1.7–17.0), |
| | p=0.004] |
| | than the |
| | younger |
| | ages with |
| | [OR (95% |
| | CI) = 1.7 (|
| | 0,9–3,1), |
| | p=0,08]. |
| | For |
| | participants |
| | aged 1 year, |
| | the SD was |
| | higher than |
| | the average |
| | [OR (95% |
| | CI) = 1,5 |
| | (0,8–2,8), |
| | p=0.18]. |

Remarks: TERA (*Triggered Escalating Remote Coaching Adherence*), the *standard of care* (SOC), act healthy (AH), electronic monitoring (eCAPs), Text Message (PT), Instant Message (Pi), Instant Message + Social Media Group (Pi+smg), Intervention (I), Control (K), Pass Away (m), loss follow up (lfu), MI(), mobile phone intervention (MPI), Medication Event Monitoring System (MEMS)

The research sites: Southern Africa (10), the United States of America (15,17,20,21,23) Thailand (14) Colombia (16), Kenya (21), Brazil, Haiti, India, Kenya, Malawi, Southern Africa, Thailand, Uganda, Zimbabwe (17) various studies discussed the potentials of phone applications for patients with chronic diseases. The mHelath technology was an effective medium to improve the excellent results for chronic diseases (24). The studies lasted from nine months (21) until five years (9, 21). The researchers recruited with various methods, including advertisement on the Internet(22), Facebook (22), partnership (22), counselor (14), online advertisement (14), community clinic brochure (16,17,21,22), and referral places (22). The male respondents 76%, gay or bisexual respondents were 71%(22), males were 52% (17), males 55% (15), males with 5% from the intervention group; males from the control group 19% female with 75% on the intervention group; females with 81% from the control group (21), males with 79,2% from the intervention group and 78,9% from the control group males with 37.5% from (20),the intervention group and 57,5% from the control group (16), female respondents with 53% (23), YMSM 74% and YTGW 26% (14).

THE ARV MEDICINE ADHERENCE

The ART optimum adherence is defined as the action of not missing any single doses or delayed doses for more than one hour within a period of a month (19). The ARV medicine adherence must be higher than 95%, indicating the medicine is consumed correctly based on the doses, manner, and time by health professionals as the efforts to reach and suppress the virus. Thus, the patients had to obey and be consistent. The disobedience against ART therapy caused HIV medication failure (14). Previous studies showed that untreated HIV and ART side effects could cause various symptoms. ART medicine could contribute to the inconvenience of the patients.

THE ADHERENCE MEASURING TOOL

The assessment of medicine consumption could be measured based on the HIV viral load or with the developed MEMS Cap; the daily medication adherence was monitored electronically within a certain period with closed MEMS. The MEMS were unsealed and recorded based on the dates and times of unsealing the caps. The autonomous reports of the blood checkup, and venipuncture, were useful to examine the HIV viral load. When the services were absent, the laboratory test was important to

check the HIV viral load. The autonomous assessment indicated the participants autonomously reported the dates and the test results of HIV viral loads in the initial assessment and follow-up assessment.

The other assessments were measured by collecting the unsealed caps from EDM Smart Bottle that recorded the dates and times of unsealing the devices and sending the information online into the data collection dashboard via a cellular network. The other measurements of adherence to ART medicine applied ACTG questionnaire, adherence for any chronic medication using the AIDS clinical trial group. High scores indicated high missing dose frequency.

The Virology Suppression

Virological suppression refers to RNA HIV-1 plasma check-up for less than 200 copies/ml in the twelfth week $(\pm 2 \text{ weeks})$ while virological failure is defined as RNA HIV-1 in the twelfth week for more than 200 copies/ml or having no viral load test (25). The results in Kenya showed that both groups had decreased viral loads, higher than 0.5 log 10 from time to time. This finding was clinically, significantly, and statistically relevant (p=0.0007). Viral load for intervention (0,96, SE=0,16 vs. 1,54, SE=0,18) while the control group was (0,80, SE=0,15 vs 1,34, SE=0,16) significantly lower in the ninth month than at the beginning of the research (21).

The research in America involved black American adults and found that viral suppression via venipuncture was 82.6% in the control group. For the intervention group, the obtained percentage was 81.1%. In terms of self-reporting, the control group obtained a percentage of 71.7% while the intervention group obtained a percentage o 73.9% (22).

CD₄ Check Up

The check-up found a higher CD4 level in 500 participants from the intervention group, 55.0%. For the control group, the obtained percentage was 51.3% (16). The

other researchers in various countries were useful to compare the intervention and the control groups; Brazil with 10%: 9%, Haiti 8%: 9%, India with 28%: 22%, Kenya with 10%: 12%, Malawi 7%: 7%, Southern Africa 15%: 17%, Thailand 2%: 5%, Uganda 16%: 15%, Zimbabwe 4%: 4% (17).

The Risky Behaviors of HIV Transmission

The consistency of applying condoms for the intervention group was only 33% while the control group was higher, 35%. The percentages were contrasting toward the inconsistency of applying condoms for the intervention group, 67%. On the other hand, the inconsistency of applying condoms for the control group was 65% (14). The possible interruptions of consuming alcohol in the intervention group were 37.5% while the control group was 25.0% (16). The measurement of compound consumption was with urinary technology and timeline (TFLB) follow-back to assess the consumption of cocaine, amphetamine, phencyclidine (PCP) tetrahydrocannabinol (THC), and opiates.

DISCUSSION

The examined intervention was explained clearly and required adaptive design to improve medicine consumption adherence. This action was useful to objectively apply and to provide easy access for all participants without having direct interaction with the researchers. Thus, the participants' positive behaviors would be positive.

The viral suppression effects did not occur significantly in the intervention group due to the focused intervention on solving the problems. For the adolescents, the detected viral load had worsening negative consequences, including worsening clinical results, such as AIDS, inpatient, mortality, chronic inflammation, repeated virological failure, and sexual disease transmission (25).

The researchers carried out the research during COVID-19. Thus, the situation indirectly hindered the sample collection step although the hindering effects were not proven. The respondents were expected to report their developments. Thus, the research results might be biased because some respondents did not report.

The measuring method of the intervention results had to be valid and reliable, by using the trusted measurement to measure the medicine consumption adherence. The viral load measurement and the CD_4 amount measurements on the individuals with different characteristics in each country required a relatively long time. The processes were also different so the results could not be generalized. Thus, the results should be considered at certain stadiums based on the respondents' conditions.

The autonomous data collection was guided by the application of the symptoms and the side effects of ARV. These matters provided an evidence-based nursing strategy that was modified to support it. The management of the medicine's side effects influenced the individual adherence to the medication because of the potential side effects of ARV.

The sampling of ARV medicine had irregular times that could change the pharmacokinetic and pharmacodynamic effects of the medicine. Thus, further monitoring and reminder were important to provide an equal dose and maximum effects of ARV medication.

The research results recommended the participation to prevent HIV transmission to save the spouses or other HIV substitutions. One of them is by having campaigns about a condom because the consistency to use condoms should be maximized.

The HIV stigma became a hindering problem for individuals suffering from HIV/AIDS to have ARV medication. This problem must be solved, for example in terms of management. The solutions might include providing information, motivation, and behavior to obey the care and ART. The other reported symptoms in this research were a significant decrease in depression and compound administration in the third and sixth months after the intervention than the control group.

The counseling of medicine consumption adherence became the key to ART medication. Thus, this medication required counseling standard implementation. Preparing individuals to get ART could provide awareness about the importance of ART to suppress HIV.

CONCLUSION

This literature review showed that ARV medication was correlated to medicine consumption behavior based on accurate suggestions. Telenursing medical was effective to improve the clients' intention to consume the medicine and to mediate the health facility distance problems. The application designs should be convenient and easy to use. The applied language should be understandable. The application should be able to be downloaded via Android. These became the alternatives to improve medicine consumption adherence.

Future studies should create appropriate application models for all age levels and sex types. This development facilitates our understanding of the friendly application for children and adolescents. The application could be adopted by various backgrounds and is applicable and understandable for all communities.

Declaration by Authors

Ethical Approval: Not Applicable Acknowledgement: None Source of Funding: None

Conflict of Interest: The researchers reported no conflict of interest The researchers took the responsibility of writing this paper.

REFERENCES

- 1. WHO. 2021;(HIV/AIDS.). Available from: https://www.who.int/news-room/factsheets/detail/hiv-aids
- 2. Anywar G, Kakudidi E, Byamukama R, Mukonzo J, Schubert A, Oryem-Origa H.

Indigenous traditional knowledge of medicinal plants used by herbalists in treating opportunistic infections among people living with HIV/AIDS in Uganda. Journal of Ethnopharmacology [Internet]. 2020;246(April 2019):112205. Available from:

https://doi.org/10.1016/j.jep.2019.112205

- Wahyuni S, Zulkifli A, Thamrin Y, Arsin AA. The effect of counseling on adherence arv therapy in HIV/AIDS patient in H.A. sulthan daeng radja bulukumba regency. Enfermeria Clinica [Internet]. 2020;30:362–6. Available from: https://doi.org/10.1016/j.enfcli.2019.10.101
- 4. Ellsworth GB, Burke LA, Wells MT, Mishra S, Caffrey M, Liddle D, et al. Randomized Pilot Study of an Advanced Bottle as Smart-Pill an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. Journal of acquired immune deficiency syndromes (1999). 2021:86(1):73-80.
- Bukenya D, Mayanja BN, Nakamanya S, Muhumuza R, Seeley J. What causes nonadherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda. AIDS Research and Therapy [Internet]. 2019;16(1):1–9. Available from: https://doi.org/10.1186/s12981-018-0214-y
- Nurfalah F, Yona S, Waluyo A. The relationship between HIV stigma and adherence to antiretroviral (ARV) drug therapy among women with HIV in Lampung, Indonesia. Enfermeria Clinica [Internet]. 2019;29:234–7. Available from: https://doi.org/10.1016/j.enfcli.2019.04.138
- 7. WHO. Global HIV Programme. World Health Organization [Internet]. 2020;HIV data and statistics. Available from: https://www.who.int/data/gho/data/themes/h iv-aids/data-on-the-size-of-the-hiv-aidsepidemic%0Ahttps://www.who.int/teams/gl obal-hiv-hepatitis-and-stisprogrammes/hiv/strategic-information/hivdata-and-statistics
- Mabuto T, Mshweshwe-Pakela N, Ntombela N, Hlongwane M, Wong V, Charalambous S, et al. Is HIV Post-test Counselling Aligned with Universal Test and Treat Goals? A Qualitative Analysis of Counselling Session Content and Delivery in South Africa. AIDS and Behavior [Internet]. 2021;25(5):1583–96. Available

from: https://doi.org/10.1007/s10461-020-03075-x

- Ismail R, Voss JG, Yona S, Nurachmah E, Boutain D, Lowe C, et al. Classifying stigma experience of women living with HIV in Indonesia through the social ecological model. Health Care for Women International [Internet]. 2022 Mar 4;43(1– 3):345–66. Available from: https://doi.org/10.1080/07399332.2021.192 9989
- Gouse H, Robbins RN, Mellins CA, Kingon A, Rowe J, Henry M, et al. Empowering Lay-Counsellors with Technology: Masivukeni, a Standardized Multimedia Counselling Support Tool to Deliver ART Counselling. AIDS and Behavior. 2018;22(10):3345–56.
- Car J, Tan WS, Huang Z, Sloot P, Franklin BD. eHealth in the future of medications management: Personalisation, monitoring and adherence. BMC Medicine. 2017;15(1):1–9.
- 12. Afik A, Pandin MGR. Telenursing as a new nursing paradigm in the 21 century: A literature review. 2021;(March). Available from: www.preprints.org
- Kemenkes R. Peraturan Kementerian Kesehatan nomor 20 Tahun 2019. Menteri Kesehatan Republik Indonesia Peraturan Menteri Kesehatan Republik Indonesia. 2019;Nomor 6588(879):2004–6.
- 14. Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, et al. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial. Journal of the International AIDS Society. 2020;23(S5):21–31.
- 15. Amico KR, Lindsey JC, Hudgens M, Dallas R, Horvath KJ, Dunlap A, et al. Randomized Controlled Trial of a Remote Coaching mHealth Adherence Intervention in Youth Living with HIV. AIDS and Behavior. 2022;26(12):3897–913.
- 16. Schnall R, Cho H, Mangone A, Pichon A, Jia H. Mobile Health Technology for Improving Symptom Management in Low Income Persons Living with HIV. AIDS and Behavior. 2018;22(10):3373–83.
- 17. Gross R, Ritz J, Hughes MD, Salata R, Mugyenyi P, Hogg E, et al. Two-way

mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. The Lancet Digital Health [Internet]. 2019;1(1):e26–34. Available from: http://dx.doi.org/10.1016/S2589-7500(19)30006-8

- Talebi-Tamijani Z, Lotfi R, Kabir K. Telecounseling based on motivational interviewing to change sexual behavior of women living with HIV: a randomized controlled clinical trial. AIDS and Behavior. 2022;26(11):3506–15.
- 19. Jiao K, Wang C, Liao M, Ma J, Kang D, Tang W, et al. A differentiated digital intervention to improve antiretroviral therapy adherence among men who have sex with men living with HIV in China: a randomized controlled trial. BMC Medicine [Internet]. 2022;20(1):1–15. Available from: https://doi.org/10.1186/s12916-022-02538-3
- YIGIT I, MODI RA, WEISER SD, JOHNSON MO, MUGAVERO MJ, TURAN JM, et al. Effects of an intervention on internalized HIV-related stigma for individuals. Aids. 2020;34(Suppl 1):S73– 82.
- Kurth AE, Sidle JE, Chhun N, Lizcano JA, Macharia SM, Garcia MM, et al. Computerbased counseling program (Care+ Kenya) to promote prevention and HIV health for people living with HIV/AIDS: A randomized controlled trial. AIDS Education and Prevention. 2019;31(5):395– 406.
- 22. Bogart LM, Mutchler MG, Goggin K, Ghosh-Dastidar M, Klein DJ, Saya U, et al. Randomized Controlled Trial of Rise, A Community-Based Culturally Congruent

Counseling Intervention to Support Antiretroviral Therapy Adherence Among Black/African American Adults Living with HIV. AIDS and Behavior [Internet]. 2022; Available from:

https://doi.org/10.1007/s10461-022-03921-0

- 23. Magidson JF, Belus JM, Seitz-Brown CJ, Tralka H, Safren SA, Daughters SB. Act Healthy: A Randomized Clinical Trial Evaluating Behavioral Activation a Intervention to Address Substance Use and Medication Adherence Among Low-Income. Black/African American Individuals Living with HIV/AIDS. AIDS and Behavior. 2022;26(1):102-15.
- 24. Schnall R, Cho H, Mangone A, Pichon A, Jia H. Mobile Health Technology for Improving Symptom Management in Low Income Persons Living with HIV. AIDS and Behavior. 2018;22(10):3373–83.
- 25. Amico KR, Lindsey JC, Hudgens M, Dallas R, Horvath KJ, Dunlap A, et al. Randomized Controlled Trial of a Remote Coaching mHealth Adherence Intervention in Youth Living with HIV. AIDS and behavior [Internet]. 2022;26(12):3897–913. Available from: https://www.embase.com/search/results?sub action=viewrecord&id=L638182765&from =export

How to cite this article: Muhammad Haris Faisal, Sri Yona. The effectiveness of face-toface Counseling and telenursing on the drug adherence for individuals suffering from HIV/AIDS. International Journal of Science & Healthcare Research. 2023; 8(2): 193-207. DOI: https://doi.org/10.52403/ijshr.20230223
